share_log

Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $45

Moomoo 24/7 ·  Apr 10 15:38

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $55 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment